TuHURA Biosciences Current Valuation vs. Total Asset
HURA Stock | 4.48 0.48 12.00% |
For TuHURA Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of TuHURA Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well TuHURA Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between TuHURA Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of TuHURA Biosciences over time as well as its relative position and ranking within its peers.
TuHURA |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TuHURA Biosciences. If investors know TuHURA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TuHURA Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of TuHURA Biosciences is measured differently than its book value, which is the value of TuHURA that is recorded on the company's balance sheet. Investors also form their own opinion of TuHURA Biosciences' value that differs from its market value or its book value, called intrinsic value, which is TuHURA Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TuHURA Biosciences' market value can be influenced by many factors that don't directly affect TuHURA Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TuHURA Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if TuHURA Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TuHURA Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
TuHURA Biosciences Total Asset vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining TuHURA Biosciences's current stock value. Our valuation model uses many indicators to compare TuHURA Biosciences value to that of its competitors to determine the firm's financial worth. TuHURA Biosciences is rated # 2 in current valuation category among its peers. It is rated # 4 in total asset category among its peers fabricating about 0.02 of Total Asset per Current Valuation. The ratio of Current Valuation to Total Asset for TuHURA Biosciences is roughly 44.38 . At present, TuHURA Biosciences' Total Assets are projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TuHURA Biosciences' earnings, one of the primary drivers of an investment's value.TuHURA Current Valuation vs. Competition
TuHURA Biosciences is rated # 2 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 5.38 Billion. TuHURA Biosciences holds roughly 193.58 Million in current valuation claiming about 4% of stocks in Biotechnology industry.
TuHURA Total Asset vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
TuHURA Biosciences |
| = | 193.58 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
TuHURA Biosciences |
| = | 4.36 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
TuHURA Total Asset Comparison
TuHURA Biosciences is currently under evaluation in total asset category among its peers.
TuHURA Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in TuHURA Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, TuHURA Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of TuHURA Biosciences' change in net profit over the period of time. It can combine multiple indicators of TuHURA Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | 18.9 K | 16.8 K | |
Operating Income | -29.8 M | -28.3 M | |
Income Before Tax | -29.3 M | -30.8 M | |
Total Other Income Expense Net | 447.9 K | 470.3 K | |
Net Loss | -29.3 M | -30.8 M | |
Net Interest Income | 71 K | 74.5 K | |
Interest Income | 89.7 K | 53.9 K | |
Net Loss | -29.3 M | -27.9 M | |
Income Tax Expense | (0.90) | (0.94) | |
Net Loss | (0.43) | (0.45) | |
Income Quality | 0.41 | 0.39 | |
Net Income Per E B T | 0.90 | 0.80 |
TuHURA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on TuHURA Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of TuHURA Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the TuHURA Biosciences' important profitability drivers and their relationship over time.
Use TuHURA Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TuHURA Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TuHURA Biosciences will appreciate offsetting losses from the drop in the long position's value.TuHURA Biosciences Pair Trading
TuHURA Biosciences Pair Trading Analysis
The ability to find closely correlated positions to TuHURA Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TuHURA Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TuHURA Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TuHURA Biosciences to buy it.
The correlation of TuHURA Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TuHURA Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TuHURA Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TuHURA Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your TuHURA Biosciences position
In addition to having TuHURA Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade TuHURA Stock refer to our How to Trade TuHURA Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
To fully project TuHURA Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of TuHURA Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include TuHURA Biosciences' income statement, its balance sheet, and the statement of cash flows.